Market Research Report
Global Cardiomyopathy Therapies Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||756739|
|Published||Content info||108 Pages
Delivery time: 1-2 business days
|Global Cardiomyopathy Therapies Market 2019-2023|
|Published: December 3, 2018||Content info: 108 Pages||
Advent of genomic medicine to push market growth during the forecast period. Cardiomyopathy is one of the major causes of heart failure. Genomic medicine is an emerging field in healthcare, it uses gene-related information of an individual. Technavio's analysts have predicted that the cardiomyopathy therapies market will register a CAGR of almost 2% by 2023.
There has been an increase in initiatives to spread awareness about cardiomyopathy among people in the last few years.
Cardiomyopathy makes it difficult for the heart to pump blood to rest of the body. The condition can be treated by surgically implanting devices within the heart, these devices are quite expensive. This high cost associated with the treatment of cardiomyopathy may pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the cardiomyopathy therapies market during the 2019-2023, view our report.
The market appears to be moderately concentrated and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the advent of genomic medicine and the initiative to increase awareness about disease, will provide considerable growth opportunities to cardiomyopathy therapies manufactures. AstraZeneca, Merck, Pfizer, and Sanofi are some of the major companies covered in this report.